Synopsis
Translate HPV and cytology combinations into the correct surveillance, colposcopy, biopsy, treatment and test-of-cure pathway while minimising avoidable excision.
- In primary HPV screening, abnormal reflex cytology with hrHPV positivity leads to colposcopy; hrHPV positivity with negative cytology enters timed repeat testing.
- After hrHPV-positive, cytology-negative screening, repeat HPV testing at 12 months; if still positive with negative cytology, repeat after another 12 months.
- At 24 months, a third consecutive hrHPV-positive result requires colposcopy regardless of the cytology result; persistence, not one isolated HPV result, drives that referral.
- If HPV is unavailable or cytology inadequate, repeat no sooner than 3 months; refer after the second consecutive unavailable or inadequate result.
- Colposcopy examines the transformation zone under magnification after acetic acid, documents adequacy and lesion extent, and directs biopsy when histology is needed.
- CIN1 often regresses and can be observed within the programme pathway; CIN3 is treated, while selected CIN2 decisions balance cancer prevention against reproductive consequences under specialist care.
- After treatment for CIN1, CIN2 or CIN3, take the HPV test of cure at 6 months: hrHPV positivity returns to colposcopy, whereas hrHPV negativity leads to a 3-year recall before routine recall can resume.
- Completely excised CGIN or SMILE has a distinct two-step test-of-cure schedule at 6 and 18 months before 3-year recall; do not apply the simpler CIN pathway.
Key red flags
A visible irregular, necrotic, ulcerated or contact-bleeding cervical mass must be managed as suspected invasive cancer rather than as a screening-grade abnormality.
Heavy bleeding that soaks pads rapidly, clots, dizziness, syncope, tachycardia or hypotension after LLETZ requires same-day emergency assessment.
Fever, escalating pelvic pain, offensive discharge or systemic illness after biopsy or excision suggests infection and needs prompt clinical review.
High-grade cytology with no matching colposcopic or histological explanation requires multidisciplinary reconciliation rather than discharge on a single reassuring view.
Pregnancy with suspected invasion requires expert colposcopy and oncology input; routine treatment should not be performed merely because HPV or CIN is present.
Investigation priorities
Determine whether an initially cytology-negative high-risk HPV infection clears, persists or develops cellular abnormality.
Management branches
An hrHPV-positive or technically inadequate screening report is issued.
- Read HPV, reflex cytology and prior results together, then tell the person clearly that the report estimates precancer risk rather than confirming cancer.
- Refer hrHPV-positive abnormal cytology to colposcopy; repeat hrHPV-positive negative cytology at 12 months and again at 24 months if still positive and cytology negative.
- Refer persistent hrHPV positivity at 24 months regardless of cytology, and repeat unavailable or inadequate testing after at least 3 months with referral after the second consecutive failure.